- Home
- TMDX vs CENT Comparison
TMDX vs CENT Comparison
Compare TMDX & CENT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMDX
- CENT
- Stock Information
- Founded
- TMDX 1998
- CENT 1955
- Country
- TMDX United States
- CENT United States
- Employees
- TMDX N/A
- CENT N/A
- Industry
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CENT Consumer Specialties
- Sector
- TMDX Health Care
- CENT Consumer Discretionary
- Exchange
- TMDX Nasdaq
- CENT Nasdaq
- Market Cap
- TMDX 2.1B
- CENT 2.5B
- IPO Year
- TMDX 2019
- CENT N/A
- Fundamental
- Price
- TMDX $57.20
- CENT $36.26
- Analyst Decision
- TMDX Buy
- CENT Strong Buy
- Analyst Count
- TMDX 11
- CENT 3
- Target Price
- TMDX $116.10
- CENT $45.00
- AVG Volume (30 Days)
- TMDX 2.6M
- CENT 122.5K
- Earning Date
- TMDX 02-24-2025
- CENT 02-05-2025
- Dividend Yield
- TMDX N/A
- CENT N/A
- EPS Growth
- TMDX N/A
- CENT N/A
- EPS
- TMDX 0.94
- CENT 1.62
- Revenue
- TMDX $401,090,000.00
- CENT $3,200,460,000.00
- Revenue This Year
- TMDX $81.61
- CENT $2.67
- Revenue Next Year
- TMDX $22.52
- CENT $2.19
- P/E Ratio
- TMDX $61.04
- CENT $22.38
- Revenue Growth
- TMDX 109.09
- CENT N/A
- 52 Week Low
- TMDX $56.03
- CENT $32.17
- 52 Week High
- TMDX $177.37
- CENT $47.48
- Technical
- Relative Strength Index (RSI)
- TMDX 35.74
- CENT 39.51
- Support Level
- TMDX $58.40
- CENT $35.65
- Resistance Level
- TMDX $67.80
- CENT $37.06
- Average True Range (ATR)
- TMDX 4.59
- CENT 1.02
- MACD
- TMDX -0.27
- CENT -0.23
- Stochastic Oscillator
- TMDX 4.44
- CENT 32.30
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
About CENT Central Garden & Pet Company
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.